News
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
Stocktwits on MSN4h
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...
TipRanks on MSN12h
Sarepta price target raised to $14 from $12 at Citi
Citi raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...
Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback